- As expected, the European Commision approves Merck's (NYSE:MRK) Keytruda (pembrolizumab), combined with carboplatin and Celgene's (NASDAQ:CELG) Abraxane (paclitaxel protein-bound), for the first-line treatment of adult patients with metastatic squamous non-small cell lung cancer (NSCLC).
- In early February, the advisory group CHMP adopted a positive opinion backing approval.